New efficacy data for ESC-based cell therapy for spinal cord injury to be presented at ISSCR
Asterias Biotherapeutics, Inc will present new 9-month efficacy and safety data from their ongoing Phase I/IIa trial for OPC-1 in a workshop and poster presentation.
At the International Society for Stem Cell Research 2017 Annual Meeting (June 14-17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9-month efficacy and safety data from their ongoing SCiStar Phase I/IIa trial of human embryonic stem cell-derived oligodendrocyte progenitor cells. The cell therapy, called OPC-1, is being trialled in subacute cervical spinal cord injury patients who receive the treatment 14—30 days post-injury.
Data from this trial was previously presented at World Advanced Therapies and Regenerative Medicine (May 17-19,2017; London, UK) and the 20th Annual Meeting American Society of Gene and Cell Therapy (ASGCT, May 10-13, 2017; DC, USA).
“The ASGCT decision to include a presentation on AST-OPC1 in its Presidential Symposium signifies the ground-breaking nature of our program, and reflects the encouraging efficacy and safety data we have seen to date in patients with severe spinal cord injuries that have been treated with AST-OPC1,” commented Steve Cartt, President and Chief Executive Officer of Asterias.
If you are attending ISSCR 2017, you can attend the Asterias workshop, titled ‘Clinical Development of hESC-derived Oligodendrocyte Progenitors for the Treatment of Spinal Cord injury’ on June 13, 2017 at 10:45am.
News of this trial, including the first preliminary data, has previously been covered on RegMedNet. Learn more about the Asterias SCiStar trial of OPC-1 in episode one of #TalkingRegMed, featuring Lauren Pulling, Editor, NeuroCentral.